Other studies have demonstrated that the expression of MSLN in the luminal membrane can be correlated with a worse prognosis than that associated with its cytoplasmic expression in gastric carcinoma, extrahepatic bile duct cancer, and breast cancer [43,44,45]. This evidence concerns the gene MSLN and breast carcinoma.